JP2017514858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514858A5 JP2017514858A5 JP2016566672A JP2016566672A JP2017514858A5 JP 2017514858 A5 JP2017514858 A5 JP 2017514858A5 JP 2016566672 A JP2016566672 A JP 2016566672A JP 2016566672 A JP2016566672 A JP 2016566672A JP 2017514858 A5 JP2017514858 A5 JP 2017514858A5
- Authority
- JP
- Japan
- Prior art keywords
- resveratrol
- composition
- ursolic acid
- effective amount
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 48
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 48
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 48
- 229940016667 resveratrol Drugs 0.000 claims description 48
- 235000021283 resveratrol Nutrition 0.000 claims description 48
- 229940096998 ursolic acid Drugs 0.000 claims description 48
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 48
- 239000000203 mixture Substances 0.000 claims description 41
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims description 6
- 208000001280 Prediabetic State Diseases 0.000 claims description 5
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 244000299461 Theobroma cacao Species 0.000 claims description 2
- 235000015173 baked goods and baking mixes Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013736 caramel Nutrition 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 235000011888 snacks Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 24
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461988859P | 2014-05-05 | 2014-05-05 | |
| US61/988,859 | 2014-05-05 | ||
| PCT/US2015/029224 WO2015171598A1 (en) | 2014-05-05 | 2015-05-05 | Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020100600A Division JP2020147590A (ja) | 2014-05-05 | 2020-06-10 | 肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514858A JP2017514858A (ja) | 2017-06-08 |
| JP2017514858A5 true JP2017514858A5 (enExample) | 2018-06-14 |
| JP6716468B2 JP6716468B2 (ja) | 2020-07-01 |
Family
ID=54392898
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016566672A Active JP6716468B2 (ja) | 2014-05-05 | 2015-05-05 | 肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物 |
| JP2020100600A Pending JP2020147590A (ja) | 2014-05-05 | 2020-06-10 | 肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020100600A Pending JP2020147590A (ja) | 2014-05-05 | 2020-06-10 | 肥満、糖尿病、または癌を治療するためのウルソル酸および／またはレスベラトロールを含む方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US10155003B2 (enExample) |
| EP (1) | EP3139910B1 (enExample) |
| JP (2) | JP6716468B2 (enExample) |
| AU (2) | AU2015256178B2 (enExample) |
| MY (1) | MY181685A (enExample) |
| WO (1) | WO2015171598A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015171598A1 (en) * | 2014-05-05 | 2015-11-12 | The Board Of Regents Of The University Of Texas System | Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer |
| US11135145B2 (en) | 2015-11-13 | 2021-10-05 | Paul John Thornally | Hesperetin and trans-resveratrol compositions and methods thereof |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| CN109248170B (zh) | 2017-07-13 | 2023-10-03 | 华东理工大学 | 靶向于pd-1的皂苷类化合物及其应用 |
| CA3075173A1 (en) * | 2017-09-13 | 2019-03-21 | Emmyon, Inc. | Ursolic acid morpholine and diethanolamine salts |
| EP4433174A4 (en) * | 2021-11-18 | 2025-10-22 | Univ Texas | COMBINATIONS OF CURCUMIN AND URSOLIC ACID AND THEIR USES |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070269537A1 (en) * | 2003-02-10 | 2007-11-22 | Bioderm Research | Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System |
| JP2006273834A (ja) * | 2004-06-28 | 2006-10-12 | Kao Corp | Ａｍｐｋ活性化剤 |
| US7772195B2 (en) | 2004-07-29 | 2010-08-10 | Board Of Trustees Of Michigan State University | Methods and compositions for the treatment of obesity, insulin related diseases and hypercholesterolemia |
| WO2008006581A2 (en) * | 2006-07-14 | 2008-01-17 | Dsm Ip Assets B.V. | Compositions and use thereof for the treatment, co-treatment or prevention of imflammatory disorders |
| US8431552B2 (en) * | 2007-01-16 | 2013-04-30 | Chien-Hung Chen | Composition for treating metabolic syndrome |
| CN101032564B (zh) * | 2007-02-28 | 2011-03-23 | 天津津酒集团有限公司 | 调节血脂养生酒及其制备方法 |
| WO2010095926A1 (en) * | 2009-02-20 | 2010-08-26 | N.V. Nutricia | Use of reveratrol for preserving cognitive functioning |
| CA2795320C (en) * | 2010-04-12 | 2019-01-22 | Reata Pharmaceuticals, Inc. | Method of treating obesity using antioxidant inflammation modulators |
| US9393221B2 (en) * | 2011-07-20 | 2016-07-19 | The General Hospital Corporation | Methods and compounds for reducing intracellular lipid storage |
| WO2014014530A1 (en) | 2012-07-17 | 2014-01-23 | Mylari Banavara L | Ursolic acid salts for treating diabetes and obesity |
| US9211298B2 (en) * | 2012-11-16 | 2015-12-15 | Song Gao | Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses |
| WO2015171598A1 (en) * | 2014-05-05 | 2015-11-12 | The Board Of Regents Of The University Of Texas System | Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer |
| ES2835874T3 (es) * | 2014-07-29 | 2021-06-23 | Shenzhen Hightide Biopharmaceutical Ltd | Sales de berberina, sales ursodesoxicólicas y combinaciones, procedimientos de preparación y aplicación de las mismas |
-
2015
- 2015-05-05 WO PCT/US2015/029224 patent/WO2015171598A1/en not_active Ceased
- 2015-05-05 US US15/308,427 patent/US10155003B2/en active Active
- 2015-05-05 MY MYPI2016704048A patent/MY181685A/en unknown
- 2015-05-05 AU AU2015256178A patent/AU2015256178B2/en not_active Ceased
- 2015-05-05 EP EP15788818.1A patent/EP3139910B1/en active Active
- 2015-05-05 JP JP2016566672A patent/JP6716468B2/ja active Active
-
2018
- 2018-12-14 US US16/221,094 patent/US10583145B2/en active Active
-
2020
- 2020-03-09 US US16/813,017 patent/US11166962B2/en active Active
- 2020-05-25 AU AU2020203419A patent/AU2020203419B2/en not_active Ceased
- 2020-06-10 JP JP2020100600A patent/JP2020147590A/ja active Pending
- 2020-07-01 US US16/918,378 patent/US11090311B2/en active Active
-
2021
- 2021-04-17 US US17/233,456 patent/US11642354B2/en active Active
- 2021-04-17 US US17/233,457 patent/US11690851B2/en active Active
- 2021-04-17 US US17/233,455 patent/US11684626B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514858A5 (enExample) | ||
| JP2018193377A5 (enExample) | ||
| JP2015212268A5 (enExample) | ||
| JP2015512406A5 (enExample) | ||
| JP2011068653A5 (enExample) | ||
| JP2016512248A5 (enExample) | ||
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2016515628A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| JP2016531885A5 (enExample) | ||
| JP2016510326A5 (enExample) | ||
| JP2020503269A5 (enExample) | ||
| JP2013541583A5 (enExample) | ||
| JP2017514853A5 (enExample) | ||
| JP2018503644A5 (enExample) | ||
| JP2017533220A5 (enExample) | ||
| WO2011151722A3 (en) | Methods and compositions for oral pharmaceutical therapy | |
| JP2016530291A5 (enExample) | ||
| JP2019501226A5 (enExample) | ||
| JP2016512247A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| Sturn et al. | Low-dose naltrexone: a new therapy option for complex regional pain syndrome type I patients | |
| JP2018506533A5 (enExample) | ||
| JP2016522188A5 (enExample) | ||
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 |